Absorption of glucagon-like peptide-1 can be protracted by zinc or protamine

International Journal of Pharmaceutics

Volumn 136, Issue 1-2, 1996, Pages 53-59

  Pridal, Lone ^a   Agerbæk, Hanne ^a   Christensen, Lone N ^a   Thomsen, Karina ^a   Kirk, Ole ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

GLP 1(7 36)amide; Glucagon like peptide 1; Pharmacokinetics; Protamine; S.c. preparations; Zinc

Indexed keywords

DRUG VEHICLE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; PROTAMINE SULFATE; UNCLASSIFIED DRUG; ZINC CHLORIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PH; PHARMACOKINETICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030012685     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(95)04480-9     Document Type: Article

References (15)

1. Adelhorst, K., Hedegaard, B.B., Knudsen, L.B. and Kirk, O., Structure-activity studies of Glucagon-like peptide-1. J. Biol. Chem., 269 (1994) 6275-6278.
2. 2-terminus in type 2 diabetic patients and in healthy subjects. Diabetes. 44 (1995) 1126-1131.
3. Elliott, R.M., Morgan, L.M., Tredger, J.A., Deacon, S., Wright, J. and Marks, V., Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in man: acute post-prandial and 24-h secretion patterns. J. Endocrinol., 138 (1993) 159-166.
4. Galloway, J.A. and Chance, R.E. Improving insulin therapy: achievements and challenges. Horm. Metab. Res., 26 (1994) 591-598.
5. Gutniak, M.D., Ørskov, C., Holst, J.J., Ahrén, B. and Efendic, S., Antidiabetogenic effect of glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med., 326 (1992) 1316-1322.
6. Gutniak, M.K., Linde, B., Holst, J.J. and Efendic, S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycaemia in NIDDM. Diabetes Care, 17 (1994) 1039-1044.
7. Heinzel, G., Woloszczak, R. and Thomann, P., (1993) Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Topfit 2.0. Gustav Fischer, Stuttgart, Germany.
8. Nauck, M.A., Kleine, N., Ørskov, C., Holst, J.J., Willms, B. and Creutzfeldt, W., Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36)amide in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 36 (1993) 741-744.
9. Pingel, M., Skelbaek-Pedersen, B. and Brange, J., In Lefébvre, P.J. (Ed.), Handbook of Experimental Pharmacology: Glucagon I. Vol 66/1, Chpt. 8. Springer-Verlag, New York, 1993.
10. Pridal, L., Ingwersen, S.H., Larsen, F.S., Holst, J.J., Adelhorst, K. and Kirk, O., Comparison of sandwich enzymelinked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-36)amide in plasma. J. Pharm. Biomed. Anal., 13 (1995) 841-850.
11. Pridal, L., Deacon, C.F., Kirk, O., Christensen, J.V., Carr, R.D. and Holst, J.J., Glucagon-like peptide(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide and is degraded more quickly by plasma in vitro in dogs. Eur. J. Drug Metab. Pharmacokinet., (1996) (submitted for publication).
12. Rachmann, J. and Turner, R.C. Drugs on the horizon for treatment of type 2 diabetes. Diabetic Med., 12 (1995) 467-478.
13. Trading, F., Nielsen, P., Pingel, M. and Vølund, Aa. Biological and chemical properties of two glucagon preparations with prolonged action. Eur. J. Pharmacol, 7 (1969) 206-210.
14. Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J. and Holst, J.J., Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci., 38 (1993) 665-673.
15. Ørskov, C., Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologica, 35 (1992) 701-711.